Actelion lodges appeal as details of fasudil ruling emerge
This article was originally published in Scrip
Executive Summary
The embattled Swiss specialty pharma firm Actelion has appealed the recent decision by a US court to award $577 million in damages to plaintiff Asahi Kasei Pharma in a case involving a terminated product licensing deal.